Cargando…
Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis
Patients with multiple myeloma (MM) have a diminished immune response to coronavirus disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to be determined. We aimed to summarize the COVID-19 vaccine immunogenicity and to identify factors that influence the humoral i...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561400/ https://www.ncbi.nlm.nih.gov/pubmed/36538342 http://dx.doi.org/10.1182/bloodadvances.2022008530 |
_version_ | 1784807945364570112 |
---|---|
author | Chuleerarux, Nipat Manothummetha, Kasama Moonla, Chatphatai Sanguankeo, Anawin Kates, Olivia S. Hirankarn, Nattiya Phongkhun, Kasidis Thanakitcharu, Jaedvara Leksuwankun, Surachai Meejun, Tanaporn Thongkam, Achitpol Mongkolkaew, Thanuthong Dioverti, M. Veronica Torvorapanit, Pattama Langsiri, Nattapong Worasilchai, Navaporn Plongla, Rongpong Chindamporn, Ariya Gopinath, Shilpa Nissaisorakarn, Pitchaphon Thaniyavarn, Tany Nematollahi, Saman Permpalung, Nitipong |
author_facet | Chuleerarux, Nipat Manothummetha, Kasama Moonla, Chatphatai Sanguankeo, Anawin Kates, Olivia S. Hirankarn, Nattiya Phongkhun, Kasidis Thanakitcharu, Jaedvara Leksuwankun, Surachai Meejun, Tanaporn Thongkam, Achitpol Mongkolkaew, Thanuthong Dioverti, M. Veronica Torvorapanit, Pattama Langsiri, Nattapong Worasilchai, Navaporn Plongla, Rongpong Chindamporn, Ariya Gopinath, Shilpa Nissaisorakarn, Pitchaphon Thaniyavarn, Tany Nematollahi, Saman Permpalung, Nitipong |
author_sort | Chuleerarux, Nipat |
collection | PubMed |
description | Patients with multiple myeloma (MM) have a diminished immune response to coronavirus disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to be determined. We aimed to summarize the COVID-19 vaccine immunogenicity and to identify factors that influence the humoral immune response in patients with MM. Two reviewers independently conducted a literature search in MEDLINE, Embase, ISI Web of Science, Cochrane library, and Clinicaltrials.gov from existence until 24 May 24 2022. (PROSPERO: CRD42021277005). A total of 15 studies were included in the systematic review and 5 were included in the meta-analysis. The average rate (range) of positive functional T-lymphocyte response was 44.2% (34.2%-48.5%) after 2 doses of messenger RNA (mRNA) COVID-19 vaccines. The average antispike antibody response rates (range) were 42.7% (20.8%-88.5%) and 78.2% (55.8%-94.2%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. The average neutralizing antibody response rates (range) were 25% (1 study) and 62.7% (53.3%-68.6%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. Patients with high-risk cytogenetics or receiving anti-CD38 therapy were less likely to have a humoral immune response with pooled odds ratios of 0.36 (95% confidence interval [95% CI], 0.18, 0.69), I(2) = 0% and 0.42 (95% CI, 0.22, 0.79), I(2) = 14%, respectively. Patients who were not on active MM treatment were more likely to respond with pooled odds ratio of 2.42 (95% CI, 1.10, 5.33), I(2) = 7%. Patients with MM had low rates of humoral and cellular immune responses to the mRNA COVID-19 vaccines. Further studies are needed to determine the optimal doses of vaccines and evaluate the use of monoclonal antibodies for pre-exposure prophylaxis in this population. |
format | Online Article Text |
id | pubmed-9561400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-95614002022-10-16 Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis Chuleerarux, Nipat Manothummetha, Kasama Moonla, Chatphatai Sanguankeo, Anawin Kates, Olivia S. Hirankarn, Nattiya Phongkhun, Kasidis Thanakitcharu, Jaedvara Leksuwankun, Surachai Meejun, Tanaporn Thongkam, Achitpol Mongkolkaew, Thanuthong Dioverti, M. Veronica Torvorapanit, Pattama Langsiri, Nattapong Worasilchai, Navaporn Plongla, Rongpong Chindamporn, Ariya Gopinath, Shilpa Nissaisorakarn, Pitchaphon Thaniyavarn, Tany Nematollahi, Saman Permpalung, Nitipong Blood Adv Systematic Review Patients with multiple myeloma (MM) have a diminished immune response to coronavirus disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to be determined. We aimed to summarize the COVID-19 vaccine immunogenicity and to identify factors that influence the humoral immune response in patients with MM. Two reviewers independently conducted a literature search in MEDLINE, Embase, ISI Web of Science, Cochrane library, and Clinicaltrials.gov from existence until 24 May 24 2022. (PROSPERO: CRD42021277005). A total of 15 studies were included in the systematic review and 5 were included in the meta-analysis. The average rate (range) of positive functional T-lymphocyte response was 44.2% (34.2%-48.5%) after 2 doses of messenger RNA (mRNA) COVID-19 vaccines. The average antispike antibody response rates (range) were 42.7% (20.8%-88.5%) and 78.2% (55.8%-94.2%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. The average neutralizing antibody response rates (range) were 25% (1 study) and 62.7% (53.3%-68.6%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. Patients with high-risk cytogenetics or receiving anti-CD38 therapy were less likely to have a humoral immune response with pooled odds ratios of 0.36 (95% confidence interval [95% CI], 0.18, 0.69), I(2) = 0% and 0.42 (95% CI, 0.22, 0.79), I(2) = 14%, respectively. Patients who were not on active MM treatment were more likely to respond with pooled odds ratio of 2.42 (95% CI, 1.10, 5.33), I(2) = 7%. Patients with MM had low rates of humoral and cellular immune responses to the mRNA COVID-19 vaccines. Further studies are needed to determine the optimal doses of vaccines and evaluate the use of monoclonal antibodies for pre-exposure prophylaxis in this population. The American Society of Hematology 2022-10-14 /pmc/articles/PMC9561400/ /pubmed/36538342 http://dx.doi.org/10.1182/bloodadvances.2022008530 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Systematic Review Chuleerarux, Nipat Manothummetha, Kasama Moonla, Chatphatai Sanguankeo, Anawin Kates, Olivia S. Hirankarn, Nattiya Phongkhun, Kasidis Thanakitcharu, Jaedvara Leksuwankun, Surachai Meejun, Tanaporn Thongkam, Achitpol Mongkolkaew, Thanuthong Dioverti, M. Veronica Torvorapanit, Pattama Langsiri, Nattapong Worasilchai, Navaporn Plongla, Rongpong Chindamporn, Ariya Gopinath, Shilpa Nissaisorakarn, Pitchaphon Thaniyavarn, Tany Nematollahi, Saman Permpalung, Nitipong Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis |
title | Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis |
title_full | Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis |
title_fullStr | Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis |
title_full_unstemmed | Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis |
title_short | Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis |
title_sort | immunogenicity of sars-cov-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561400/ https://www.ncbi.nlm.nih.gov/pubmed/36538342 http://dx.doi.org/10.1182/bloodadvances.2022008530 |
work_keys_str_mv | AT chuleeraruxnipat immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT manothummethakasama immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT moonlachatphatai immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT sanguankeoanawin immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT katesolivias immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT hirankarnnattiya immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT phongkhunkasidis immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT thanakitcharujaedvara immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT leksuwankunsurachai immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT meejuntanaporn immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT thongkamachitpol immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT mongkolkaewthanuthong immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT diovertimveronica immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT torvorapanitpattama immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT langsirinattapong immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT worasilchainavaporn immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT plonglarongpong immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT chindampornariya immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT gopinathshilpa immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT nissaisorakarnpitchaphon immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT thaniyavarntany immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT nematollahisaman immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis AT permpalungnitipong immunogenicityofsarscov2vaccinesinpatientswithmultiplemyelomaasystematicreviewandmetaanalysis |